Neoadjuvant Chemotherapy with S-1 for Patients with Oral Squamous Cell Carcinoma

Oral squamous cell carcinomas (OSCCs), the most common cancer of the head and neck, accounts for over 300,000 new cancer cases worldwide annually (Lippman et al., 2005). If detected at an early stage, survival from oral cancer exceeds 90% at 5 year, whereas the survival with a diagnosis of late-stage disease is only 30%. The most important prognosticator of survival in OSCC is the presence of regional lymph node metastasis (Spiro and strong, 1971). Therefore, the surgery, including neck dissection, has been the mainstay of treatment for primary OSCCs.